The First Drug for an 'Always Hungry' Disease Just Hit a Wall

Vykat earned its approval through a clever (if unusual) trial design: a 16-week randomized withdrawal study. Researchers first put patients on the drug, then randomly pulled some off it to see what happened. The answer was pretty definitive. Patients who lost access to Vykat got significantly hungrier, as measured by a validated hyperphagia questionnaire (P = 0.0022). They also gained more weight and saw their BMI climb faster than those who stayed on the drug.

Notably, no serious adverse events occurred in the Vykat treatment arm during the pivotal trial. Nobody dropped out because of side effects, either. The edema signals were there, but they were described as low-severity. And crucially, no one died.

Longer-term data told a similarly encouraging story. Patients who restarted Vykat after being pulled off it saw their hyperphagia scores improve by 4.5 points at 13 weeks, 5.5 points at 26 weeks, and 6.3 points at two years. Behavioral symptoms improved across all six measured domains. BMI stayed relatively stable.

So the clinical trial picture looked clean. The real world is painting something messier.

Why the Gap Between Trials and Reality Matters

This is one of the oldest tensions in drug development: controlled trials vs. the chaos of clinical practice. Trials enroll carefully selected patients. Doctors follow rigid protocols. Monitoring is constant. The real world has none of those guardrails.

PWS patients are medically complex. Many have sleep apnea, obesity, diabetes risk, and behavioral challenges layered on top of the core hunger drive. When you introduce a drug that can cause fluid retention and blood sugar spikes into that population, the margin for error shrinks. The advocacy groups' statement called for "careful patient selection" and "close monitoring," which is a polite way of saying: not every doctor prescribing this drug may be treating the right patients, or watching them closely enough.

Neurocrine's CEO has said the company does not see a causal relationship between Vykat and the reported deaths, though the company has signaled that label or guidance changes are possible. That's a measured response, but it also leaves room for the situation to evolve.

Wall Street's Verdict: Cautious, Not Panicked

Investors reacted, but they didn't stampede for the exits. Neurocrine shares dropped between 3% and 6% depending on the trading window, which for a safety scare in your newest product is relatively contained.

Analysts are largely holding the line. Stifel reiterated a Buy rating and still sees Vykat reaching over $1 billion in peak sales, while acknowledging that near-term growth could be bumpy. Truist echoed the billion-dollar peak revenue target. The most bullish voice, BMO Capital Markets, projected roughly $450 million in 2026 sales and over $2 billion worldwide by the mid-2030s.

The bull case rests on a simple fact: Vykat has zero approved competitors for PWS hyperphagia. The pipeline includes some interesting candidates (pitolisant from Harmony Biosciences, plus early-stage programs targeting bitter taste receptors, PDE-10, and the MC4R pathway), but none are close to market. For now, Vykat is the only game in town.

The bear case is equally straightforward. Safety concerns in a small, vulnerable patient population can snowball. If the FDA requests stronger warnings, restricts prescribing, or (worst case) requires additional studies, adoption could stall. Integration costs and launch uncertainty add to the pressure.

What Happens Next

The advocacy groups framed their statement as a call for awareness, not a call to pull the drug. That distinction matters. These are organizations that fought for years to get any treatment approved. They're not trying to torpedo Vykat; they're trying to make sure it's used safely.

The next few months will be telling. Watch for three things: whether the FDA requests any label changes, whether new adverse event reports continue at the same pace, and whether prescribing patterns shift as the safety conversation reaches more clinicians.

For the PWS community, this is a bittersweet moment. They finally have a drug that works, and now they have to figure out how to use it without losing patients along the way. It's the kind of problem nobody wants, but it beats having no treatment at all.

Lilly's Next Blockbuster Isn't Even Approved Yet. The Black Market Didn't Wait.

Eli Lilly just sued six companies for selling its experimental obesity drug retatrutide on the black market, and the drug isn't even FDA-approved yet. The lawsuits reveal a booming underground trade that Lilly says spans 14,000 flagged listings across 100+ countries.